Diversion Control Homepage Diversion Control Homepage Privacy Policy Contact Us What's New Hot Items Site Map Search Diversion SiteDEA Diversion Control Program Logo and Banner

 

Federal Register Notices > Importers > Lannett Company Incorporated

Notice of Application 2007


FR Doc E7-18497 [Federal Register: September 19, 2007 (Volume 72, Number 181)] [Notices] [Page 53605-53606] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr19se07-119]


DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II and prior to issuing a registration under 21 U.S.C. 952(a) authorizing the importation of such substances, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on October 10, 2006, Lannett Company Incorporated, 9001 Torresdale Avenue, Philadelphia, Pennsylvania 19136, made application by letter and subsequent renewal on February 19, 2007 to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances:

Drug Schedule
Tetrahydrocannabinols (7370) I
Methylphenidate (1724) II
Morphine (9300) II

The company plans to import the basic classes of controlled substances for analytical testing on a formulated product for submission to U.S. Food and Drug Administration (FDA) for generic product approval.

Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of

[[Page 53606]]

controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 19, 2007.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745-43746), all applicants for registration to import a basic class of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: September 12, 2007.

Joseph T. Rannazzisi, 
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7-18497 Filed 9-18-07; 8:45 am]

BILLING CODE 4410-09-P

NOTICE: This is an unofficial version. An official version of these publications may be obtained directly from the Government Printing Office (GPO).


     HOME

CONTACT US

SEARCH

BACK TO TOP